Page 2 - Veronica Eames News Today

November 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on...

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, November 2, 2023- Cidara Therapeutics, Inc. , a biotechnology company...

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted th...

Proceeds expected to fund the following:

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3If...

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 -- Aligos Therapeutics, Inc. , a clinical...

SAN DIEGO, July 20, 2023 -- Cidara Therapeutics, Inc. , a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious...

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively highlight company’s progress advanc...